Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial -

4 hours ago

Liraglutide, a GLP-1 receptor agonist, was studied for its effects on obstructive sleep apnea (OSA) and health-related quality of life (HRQoL) in individuals with obesity and COPD.
The study was a secondary analysis of a randomized controlled trial involving 40 participants who were given either liraglutide (3.0 mg) or placebo for 40 weeks.
OSA was diagnosed in 84% of participants, with higher prevalence in the placebo group (85%) compared to the liraglutide group (70%).
Liraglutide significantly reduced OSA severity, with notable decreases in Apnea-Hypopnea Index (-9.87 events/h) and Oxygen Desaturation Index (-10.16 events/h).
No significant changes were observed in daytime sleepiness (Epworth Sleepiness Scale scores).
Improvements in HRQoL were noted in the General Health Perception and Role Physical subdomains of the SF-36v2 questionnaire.
The study highlights the commonality of OSA in individuals with obesity and COPD and suggests potential benefits of liraglutide in managing OSA severity and improving certain aspects of HRQoL.

Hasty Briefsbeta